Gene Therapy As a Potential Tool for Treating Neuroblastoma-a Focused Review

Overview

Journal Cancer Gene Ther

Specialties Genetics
Oncology
Pharmacology

Date 2016 Apr 16

PMID 27080224

Citations 6

Authors

M D Kumar

A Dravid

A Kumar

D Sen

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma, a solid tumor caused by rapid division of undifferentiated neuroblasts, is the most common childhood malignancy affecting children aged <5 years. Several approaches and strategies developed and tested to cure neuroblastoma have met with limited success due to different reasons. Many oncogenes are deregulated during the onset and development of neuroblastoma and thus offer an opportunity to circumvent this disease if the expression of these genes is restored to normalcy. Gene therapy is a powerful tool with the potential to inhibit the deleterious effects of oncogenes by inserting corrected/normal genes into the genome. Both viral and non-viral vector-based gene therapies have been developed and adopted to deliver the target genes into neuroblastoma cells. These attempts have given hope to bringing in a new regime of treatment against neuroblastoma. A few gene-therapy-based treatment strategies have been tested in limited clinical trials yielding some positive results. This mini review is an attempt to provide an overview of the available options of gene therapy to treat neuroblastoma.

Citing Articles

Active legumain promotes invasion and migration of neuroblastoma by regulating epithelial-mesenchymal transition.

Zhang M, Zhu J, Wang W, Jiang Z Open Life Sci. 2022; 17(1):676-685.

PMID: 35800070 PMC: 9214917. DOI: 10.1515/biol-2022-0012.

Neuroblastoma Cell Death Induced by eEF1A2 Knockdown Is Possibly Mediated by the Inhibition of Akt and mTOR Phosphorylation.

Khwanraj K, Dharmasaroja P Int J Hematol Oncol Stem Cell Res. 2022; 15(4):221-229.

PMID: 35291668 PMC: 8888357. DOI: 10.18502/ijhoscr.v15i4.7477.

Evaluation and Optimization of Poly-d-Lysine as a Non-Natural Cationic Polypeptide for Gene Transfer in Neuroblastoma Cells.

Sanchez-Martos M, Martinez-Navarrete G, Bernabeu-Zornoza A, Humphreys L, Fernandez E Nanomaterials (Basel). 2021; 11(7).

PMID: 34361142 PMC: 8308159. DOI: 10.3390/nano11071756.

Biodegradable Gene Carriers Containing Rigid Aromatic Linkage with Enhanced DNA Binding and Cell Uptake.

Zhang J, Yang H, Zhang J, Liu Y, He X, Xiao Y Polymers (Basel). 2019; 10(10).

PMID: 30961005 PMC: 6403675. DOI: 10.3390/polym10101080.

Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs.

Jaen M, Vila L, Elias I, Jimenez V, Rodo J, Maggioni L Mol Ther Methods Clin Dev. 2017; 6:1-7.

PMID: 28626777 PMC: 5466581. DOI: 10.1016/j.omtm.2017.03.008.

References

Schlehofer J . The tumor suppressive properties of adeno-associated viruses. Mutat Res. 1994; 305(2):303-13. DOI: 10.1016/0027-5107(94)90250-x. View

Farrell C, Zaupa C, Barnard Z, Maley J, Martuza R, Rabkin S . Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res. 2008; 14(23):7711-6. PMC: 2670995. DOI: 10.1158/1078-0432.CCR-08-1364. View

Kim N, Im K, Lim J, Jeon E, Nam Y, Kim E . Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Ann Hematol. 2013; 92(10):1295-308. DOI: 10.1007/s00277-013-1796-z. View

Pesonen S, Helin H, Nokisalmi P, Escutenaire S, Ribacka C, Sarkioja M . Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncol. 2009; 49(1):117-9. DOI: 10.3109/02841860903071369. View

Parikh N, Currier M, Mahller Y, Adams L, Di Pasquale B, Collins M . Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer. 2004; 44(5):469-78. DOI: 10.1002/pbc.20268. View

Boyman O, Sprent J . The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012; 12(3):180-90. DOI: 10.1038/nri3156. View

Sen D, Balakrishnan B, Gabriel N, Agrawal P, Roshini V, Samuel R . Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy. Sci Rep. 2013; 3:1832. PMC: 3652085. DOI: 10.1038/srep01832. View

Toes R, Ossendorp F, Offringa R, Melief C . CD4 T cells and their role in antitumor immune responses. J Exp Med. 1999; 189(5):753-6. PMC: 2192956. DOI: 10.1084/jem.189.5.753. View

Bell P, Moscioni A, McCarter R, Wu D, Gao G, Hoang A . Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther. 2006; 14(1):34-44. DOI: 10.1016/j.ymthe.2006.03.008. View

10.

Steffens S, Sandquist A, Frank S, Fischer U, Lex C, Rainov N . A neuroblastoma-selective suicide gene therapy approach using the tyrosine hydroxylase promoter. Pediatr Res. 2004; 56(2):268-77. DOI: 10.1203/01.PDR.0000132666.23103.EF. View

11.

Wong H, Lemoine N, Wang Y . Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles. Viruses. 2010; 2(1):78-106. PMC: 2883714. DOI: 10.3390/v2010078. View

12.

Cross D, Burmester J . Gene therapy for cancer treatment: past, present and future. Clin Med Res. 2006; 4(3):218-27. PMC: 1570487. DOI: 10.3121/cmr.4.3.218. View

13.

Nomura M, Shimbo T, Miyamoto Y, Fukuzawa M, Kaneda Y . 13-Cis retinoic acid can enhance the antitumor activity of non-replicating Sendai virus particle against neuroblastoma. Cancer Sci. 2012; 104(2):238-44. PMC: 7657131. DOI: 10.1111/cas.12063. View

14.

Amer M . Gene therapy for cancer: present status and future perspective. Mol Cell Ther. 2015; 2:27. PMC: 4452068. View

15.

Garcia-Castro J, Alemany R, Cascallo M, Martinez-Quintanilla J, Arriero M, Lassaletta A . Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther. 2010; 17(7):476-83. DOI: 10.1038/cgt.2010.4. View

16.

Hueng D, Lin G, Huang S, Liu L, Ju D, Chen Y . Inhibition of Nodal suppresses angiogenesis and growth of human gliomas. J Neurooncol. 2010; 104(1):21-31. DOI: 10.1007/s11060-010-0467-3. View

17.

Sen D . Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering. J Biomed Sci. 2014; 21:103. PMC: 4251935. DOI: 10.1186/s12929-014-0103-1. View

18.

DAlessio G . New and cryptic biological messages from RNases. Trends Cell Biol. 1993; 3(4):106-9. DOI: 10.1016/0962-8924(93)90166-x. View

19.

Fredlund E, Ringner M, Maris J, Pahlman S . High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A. 2008; 105(37):14094-9. PMC: 2544584. DOI: 10.1073/pnas.0804455105. View

20.

Dulamea A . Mesenchymal stem cells in multiple sclerosis - translation to clinical trials. J Med Life. 2015; 8(1):24-7. PMC: 4397514. View